HCs (n = 109) had lower levels of PSA, did not have cancer or other known comorbidities, and were also younger than the BPH and PCa cohorts by an average of 6 and 3 years respectively (p-values of <0.001 and 0.03). This evidence concerns the gene KLK3 and benign prostatic hyperplasia.